The biotech received welcome news from the FDA for lead CBD candidate Zygel.
News & Analysis: Zynerba Pharmaceuticals
An analyst's optimistic outlook provided a spark for the small biotech.
Talk about buzzkills! These five pot stocks all fell by at least 19% last month.
Zynerba faces some big questions heading into the new year.
Whether it's a single-drug portfolio or little cash on hand, these drug developers are the definition of risk.
The third time's the charm for this cannabinoid-based drug developer.
One more clinical failure and shareholders might leave and never look back.
While most pot stocks have at least doubled in value over the past 12 months, these two are down nearly 40%!
These cannabinoid-based drug developers have recently gone up in smoke.
This clinical-stage cannabinoid-based drug developer has a long way to go to prove its worth to investors.